Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2010-04-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 151
- Registration Number
- NCT00723216
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1003
- Registration Number
- NCT00721760
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1150
- Registration Number
- NCT00718224
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)
- Conditions
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 910
- Registration Number
- NCT00718471
- Locations
- 🇫🇷
La Pitié-Salpétrière Hospital - Cardiology department, Paris, France
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
- Conditions
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 740
- Registration Number
- NCT00718354
- Locations
- 🇮🇳
Cancer Hospital & Research Institute, Cancer Hill, Gwalior, MP, India
🇮🇳Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, UP, India
🇮🇳Biswajit Sanyal, Calcutta, West Bengal, India
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
- Conditions
- Interventions
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 421
- Registration Number
- NCT00714597
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Oulu
- Target Recruit Count
- 320
- Registration Number
- NCT00699465
- Locations
- 🇫🇮
Department of Neurology, Oulu University Hospital, Oulu, Finland
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2326
- Registration Number
- NCT00697099
- Locations
- 🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
🇨🇳Sanofi-Aventis Administraive Office, Taipei, Taiwan
🇺🇦Sanofi-Aventis Administrative Office, Kiev, Ukraine
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4413
- Registration Number
- NCT00679588
- Locations
- 🇺🇸
Investigational Site Number 840036, Springfield, Illinois, United States
🇺🇸Investigational Site Number 840007, Huntingdon Beach, California, United States
🇺🇸Investigational Site Number 840017, Jacksonville, Florida, United States
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2055
- Registration Number
- NCT00657150
- Locations
- 🇺🇸
1160.64.01003 Boehringer Ingelheim Investigational Site, Missoula, Montana, United States
🇺🇸1160.64.01002 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇨🇦1160.64.6011 Boehringer Ingelheim Investigational Site, Oshawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.